keyword
MENU ▼
Read by QxMD icon Read
search

Stage IV lung cancer

keyword
https://www.readbyqxmd.com/read/28105350/interstitial-pneumonia-following-administration-of-pegfilgrastim-during-carboplatin-and-etoposide-chemotherapy-for-small-cell-lung-cancer
#1
Masayuki Shirasawa, Yoshiro Nakahara, Hideyuki Niwa, Shinya Harada, Takahiro Ozawa, Seiichiro Kusuhara, Masashi Kasajima, Yasuhiro Hiyoshi, Jiichiro Sasaki, Noriyuki Masuda
Pegfilgrastim is a long-acting granulocyte colony-stimulating factor formulation that has been approved for the prevention of febrile neutropenia. We herein report a case of interstitial pneumonia following administration of pegfilgrastim. A 65-year-old man with stage IV small-cell lung cancer was treated with carboplatin and etoposide as third-line chemotherapy. Pegfilgrastim was administered during the second cycle of chemotherapy. On the day after the administration of pegfilgrastim, interstitial pneumonia developed...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28105168/relationship-between-mir-7-expression-and-treatment-outcomes-with-gefitinib-in-non-small-cell-lung-cancer
#2
Kun Mou, Weiwei Gu, Cuihua Gu, Jinzhong Zhang, Wenjie Qwang, Gang Ren, Jing Tian
The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR-7 in patients with non-small cell lung cancer (NSCLC). A total of 126 patients were enrolled in the present study (stage I-II, n=54 and stage III-IV, n=72). Patients with stage I-II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III-IV disease. Serum levels of miR-7 before and after treatment were measured with quantitative polymerase chain reaction using fluorogenic probes, and miR-7 positivity and scoring in resected specimens were determined by immunohistochemistry...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28103974/-phase-i-study-of-etoposide-and-cisplatin-chemotherapy-dose-escalation-%C3%A2-with-concurrent-twice-daily-radiotherapy-for-patients-%C3%A2-with-limited-stage-small-cell-lung-cancer
#3
Jing You, Huiming Yu, Maxiaowei Song, Chen Shi, Xiaohang Wang, Ye Zheng, Rong Yu, Anhui Shi, Guangying Zhu
BACKGROUND: Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer. METHODS: Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28102935/ectopic-cushing-syndrome-in-small-cell-lung-cancer-a-case-report-and-literature-review
#4
Hang-Yu Zhang, Jun Zhao
Small cell lung cancer (SCLC) is a neuroendocrine tumor with the potential to secrete various peptides or hormones that can lead to paraneoplastic syndromes, such as Ectopic Cushing syndrome (ECS). Because of the aggressive nature of the syndrome and its atypical features, ECS in small-cell lung cancer is difficult to diagnose and has a poor prognosis. We report a case of a 74-year-old male patient who presented with severe hypokalemia, proximal muscle weakness, peripheral edema, metabolic alkalosis, and worsening hyperglycemia...
November 8, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/28098899/analysis-of-gene-expression-profiles-of-non-small-cell-lung-cancer-at-different-stages-reveals-significantly-altered-biological-functions-and-candidate-genes
#5
Jin Wang, Jianxiang Song, Zhengya Gao, Xudong Huo, Yajun Zhang, Wencai Wang, Jianwei Qi, Shiying Zheng
We attempt to dissect the pathology of non-small cell lung cancer (NSCLC) patients at different stages and discover the novel candidate genes. Microarray data (GSE21933) were retrieved from the Gene Expression Omnibus database. The differential expression profiles of lung tumor tissues during different stages were analyzed. The significantly altered functions and pathways were assessed and the key nodes in a protein-protein interaction (PPI) network were screened out. Then, the coexpression gene pairs and tumor-related genes were assessed...
January 17, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28088809/fibroblast-growth-factor-receptor-1-fgfr1-partly-related-to-vascular-endothelial-growth-factor-receptor-2-vegfr2-and-microvessel-density-is-an-independent-prognostic-factor-for-non-small-cell-lung-cancer
#6
Dan Pu, Jiewei Liu, Zhixi Li, Jiang Zhu, Mei Hou
BACKGROUND This study aimed to explore the correlation between FGFR1 and clinical features, including survival analysis and the promotion of angiogenesis by fibroblast growth factor receptor 1 (FGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2). FGFR1 gene amplification has been found in non-small cell lung cancer (NSCLC). However, the prognostic value of FGFR1 and the correlation between FGFR1 and clinical features are still controversial. MATERIAL AND METHODS A total of 92 patients with NSCLC who underwent R0 resection between July 2006 and July 2008 were enrolled in the study...
January 15, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28081275/role-of-xrcc1-gene-polymorphisms-in-non-small-cell-lung-cancer-cisplatin-based-chemotherapy-and-their-effect-on-clinical-and-pathological-characteristics
#7
H F Liu, J S Liu, J H Deng, R R Wu
Non-small cell lung cancer (NSCLC) is the most common cancer globally. The XRCC1 protein interacts with ligase and poly(ADP-ribose) polymerase to repair cisplatin-induced DNA damage. The authors of previous studies have reported XRCC1 Arg399Gln, Arg280His, and Arg194Trp polymorphisms and advanced NSCLC prognosis, but the results are inconclusive. We investigated the association between clinical outcome and XRCC1 Arg399Gln, Arg280His, and Arg194Trp polymorphisms in advanced NSCLC patients treated with cisplatin...
December 23, 2016: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28065465/a-multicenter-double-blind-phase-ii-study-of-metformin-with-gefitinib-as-first-line-therapy-of-locally-advanced-non-small-cell-lung-cancer
#8
Kun-Lin Li, Li Li, Peng Zhang, Jun Kang, Yu-Bo Wang, Heng-Yi Chen, Yong He
We present the rationale and study design of the CGMT (combined gefitinib and metformin therapy) trial (www.ClinicalTrials.gov Identifier: NCT01864681), which is aimed at treating locally advanced non-small-cell lung cancer. The CGMT trial is a multicenter, phase II randomized, double-blinded, and placebo-controlled study, which is designed to evaluate the safety and efficacy of metformin in combination with gefitinib as first-line therapy in patients presenting with stage IIIb-IV non-small-cell lung cancer expressing the epidermal growth factor receptor mutant...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28063177/comparable-clinical-outcomes-in-patients-with-her2-mutant-and-egfr-mutant-lung-adenocarcinomas
#9
Chien-Hung Gow, Hou-Tai Chang, Chor-Kuan Lim, Chao-Yu Liu, Jin-Shing Chen, Jin-Yuan Shih
HER2 is a major proliferative driver in lung cancer. HER2 gene aberrations impact the prognosis of lung adenocarcinoma (ADC). A one-step reverse transcription-polymerase chain reaction was performed using RNA samples from 888 Asian lung cancer patients to detect HER2, EGFR, KRAS, ALK, and ROS1 mutations. The demographic data and treatment outcomes of HER2 mutation-positive lung ADC patients were analyzed and compared to those with HER2 mutation-negative tumors. HER2 mutation was identified in 40 (4.5%) lung ADC patients...
January 7, 2017: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/28061541/a-prospective-multicenter-phase-ii-trial-of-low-dose-erlotinib-as-maintenance-treatment-after-platinum-doublet-chemotherapy-for-advanced-non-small-cell-lung-cancer-harboring-egfr-mutation
#10
Satoshi Hirano, Go Naka, Yuichiro Takeda, Motoyasu Iikura, Noriko Hayama, Asako Yanagisawa, Hiroyuki Amano, Makoto Nakamura, Sukeyuki Nakamura, Hiroshi Tabeta, Haruhito Sugiyama
BACKGROUND: Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. However, 150 mg/day of erlotinib seems too toxic as maintenance therapy. This study aimed to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment after platinum doublet chemotherapy in NSCLC harboring epidermal growth factor receptor (EGFR) mutation. METHODS: Activated EGFR-mutation-positive NSCLC patients who did not progress after first-line platinum-doublet chemotherapy, ≥20 and ≤85 years old, with performance status (PS) 0-3 were included in this study...
December 2016: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28050695/interval-lung-cancer-after-a-negative-ct-screening-examination-ct-findings-and-outcomes-in-national-lung-screening-trial-participants
#11
David S Gierada, Paul F Pinsky, Fenghai Duan, Kavita Garg, Eric M Hart, Ella A Kazerooni, Hrudaya Nath, Jubal R Watts, Denise R Aberle
OBJECTIVES: This study retrospectively analyses the screening CT examinations and outcomes of the National Lung Screening Trial (NLST) participants who had interval lung cancer diagnosed within 1 year after a negative CT screen and before the next annual screen. METHODS: The screening CTs of all 44 participants diagnosed with interval lung cancer (cases) were matched with negative CT screens of participants who did not develop lung cancer (controls). A majority consensus process was used to classify each CT screen as positive or negative according to the NLST criteria and to estimate the likelihood that any abnormalities detected retrospectively were due to lung cancer...
January 3, 2017: European Radiology
https://www.readbyqxmd.com/read/28046008/cell-free-dna-provides-a-good-representation-of-the-tumor-genome-despite-its-biased-fragmentation-patterns
#12
Xiangyuan Ma, Liangjun Zhu, Xue Wu, Hua Bao, Xiaonan Wang, Zhili Chang, Yang W Shao, Zhenxin Wang
Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded DNA found in plasma. Plasma of patients with solid tumor has been found to show significantly increased quantities of cfDNA. Although currently poorly understood, the mechanism of cfDNA generation is speculated to be a product of genomic DNA fragmentation during cellular apoptosis and necrosis. Sequencing of cfDNA with tumor origin has identified tumor biomarkers, elucidating molecular pathology and assisting in accurate diagnosis. In this study, we performed whole-genome sequencing ofcfDNA samples with matching tumor and whole blood samples from five patients diagnosed with stage IV gastric or lung cancer...
2017: PloS One
https://www.readbyqxmd.com/read/28043773/pulmonary-sarcomatoid-carcinoma-an-analysis-of-the-national-cancer-data-base
#13
Conor E Steuer, Madhusmita Behera, Yuan Liu, Chao Fu, Theresa W Gillespie, Nabil F Saba, Dong M Shin, Rathi N Pillai, Suchita Pakkala, Taofeek K Owonikoko, Fadlo R Khuri, Suresh S Ramalingam
INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a grouping of 5 rare non-small-cell lung cancer (NSCLC) subtypes. We studied the clinical characteristics and outcomes of PSC utilizing the National Cancer Data Base (NCDB), an oncology outcomes database. METHODS: The NCDB lung cancer database was queried from 1998 to 2011 for PSC using ICD-O-3 codes. Data were extracted for patient demographics, tumor pathology, treatment, and outcomes. Overall survival (OS) data were available for patients diagnosed from 1998 to 2006 and comorbidity data from 2003 to 2011...
December 7, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28032090/efficacy-and-toxicity-profile-of-maintenance-pemetrexed-in-patients-with-stage-iv-adenocarcinoma-lung-in-indian-population
#14
Goyal Pankaj, Batra Ullas, Dinesh Chandra Doval, Jain Parveen, Upadhyay Kumar Amitabh, Prasanta Kumar Dash, Jain Akhil, Mohit Agarwal, Bajaj Rajat
CONTEXT: Lung cancer has been the most common cancer in the world for several decades. Pemetrexed is recommended as an option for the maintenance treatment in metastatic adenocarcinoma lung, if disease has not progressed immediately following platinum-based chemotherapy. AIMS: To study efficacy and toxicity profile of pemetrexed as a maintenance chemotherapeutic agent in patients with stage IV adenocarcinoma lung, not progressing after first line chemotherapy. Settings and Design: This was an observational, prospective...
October 2016: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28031840/concomitant-t790m-mutation-and-small-cell-lung-cancer-transformation-after-acquired-resistance-to-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor
#15
Kohei Fujita, Young Hak Kim, Akihiko Yoshizawa, Tadashi Mio, Michiaki Mishima
A 70-year-old man was admitted to our hospital with an abnormal chest X-ray shadow. Bronchoscopy revealed an adenocarcinoma tumour with an epidermal growth factor receptor (EGFR) exon 19 deletion. Positron emission tomography-computed tomography scanning and magnetic resonance imaging showed advanced stage IV lung cancer. He was treated with erlotinib as a first-line drug, which maintained a clinical response for 16 months. After disease progression, a re-biopsy was done from the tumour in the right lower lobe...
January 2017: Respirology Case Reports
https://www.readbyqxmd.com/read/28031832/effectiveness-of-afatinib-in-lung-cancer-with-paralytic-ileus-due-to-peritoneal-carcinomatosis
#16
Haruki Kobayashi, Kazushige Wakuda, Toshiaki Takahashi
A 61-year-old never-smoking woman with stage IV lung adenocarcinoma with initially unknown epidermal growth factor receptor (EGFR) status, lung metastasis, pleural dissemination, and malignant pleural effusion in 2007 received 10 prior anti-cancer regimens including gefitinib as second- and ninth-line treatments, with minimal efficacy with gefitinib. EGFR mutation analysis performed in pleural effusion specimens during ninth-line gefitinib was negative. In 2015, she developed progressive disease with peritoneal dissemination...
November 2016: Respirology Case Reports
https://www.readbyqxmd.com/read/28030859/clinical-efficacy-of-afatinib-treatment-for-a-patient-with-leptomeningeal-carcinomatosis
#17
Yo Kawaguchi, Jun Hanaoka, Hideki Hayashi, Naoki Mizusaki, Hirotoshi Iihara, Yoshinori Itoh, Tadashi Sugiyama
Leptomeningeal metastases occur in 1% of patients with non-small-cell lung cancer. There have been several reports on the treatment of leptomeningeal metastases with afatinib. Our patient was a 41-year-old woman who had never smoked and was diagnosed with stage IV adenocarcinoma of the lung with an epidermal growth factor receptor (EGFR) mutation. She was treated with afatinib for the recurrence of leptomeningeal metastases. After the treatment with afatinib was initiated, the neurological symptoms dramatically regressed, and she achieved progression-free survival for 7 months...
December 29, 2016: Chemotherapy
https://www.readbyqxmd.com/read/28029530/survival-of-asian-females-with-advanced-lung-cancer-in-the-era-of-tyrosine-kinase-inhibitor-therapy
#18
Daniel J Becker, Juan P Wisnivesky, Michael L Grossbard, Abraham Chachoua, D Ross Camidge, Benjamin P Levy
INTRODUCTION: We examined the effect of access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on survival for Asian female (AF) EGFR mutation-enriched patients with advanced lung adenocarcinoma. MATERIALS AND METHODS: We used the Surveillance Epidemiology and End Results database to study patients with stage IV lung adenocarcinoma diagnosed from 1998 to 2012. We compared survival (lung cancer-specific survival [LCSS] and overall survival) between AFs and non-Asian males (NAMs), an EGFR mutation-enriched and EGFR mutation-unenriched population, respectively, with a diagnosis in the pre-EGFR TKI (1998-2004) and EGFR TKI (2005-2012) eras...
October 5, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28027731/pathologic-findings-and-long-term-results-after-surgical-treatment-for-pulmonary-sarcomatoid-tumors-a-multicenter-analysis
#19
Filippo Lococo, Cristian Rapicetta, Giuseppe Cardillo, Alessandro Stefani, Stefano Margaritora, Giovanni Leuzzi, Giulio Rossi, Leonardo Petracca Ciavarella, Uliano Morandi, Francesco Facciolo, Tommaso Ricchetti, Alfredo Cesario, Massimiliano Paci
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a very rare subtype of non-small cell lung cancer (NSCLC). The aim of this study was to clarify the pathologic characteristics and long-term survival after surgical treatment in patients with PSC. METHODS: From January 2003 to December 2013, we retrospectively reviewed the clinical findings, surgical notes, and pathologic and follow-up data from 148 consecutive patients who underwent curative resection for PSC in 5 institutions...
December 24, 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28026133/role-of-increased-mean-platelet-volume-mpv-and-decreased-mpv-platelet-count-ratio-as-poor-prognostic-factors-in-lung-cancer
#20
Muhyettin Omar, Ozgur Tanriverdi, Suna Cokmert, Esin Oktay, Ozlem Yersal, Kezban Nur Pilancı, Serkan Menekse, Muharrem Kocar, Cenk Ahmet Sen, Cetin Ordu, Gamze Goksel, Nezih Meydan, Sabri Barutca
OBJECTIVES: In this study, we investigated whether mean thrombocyte volume (MPV) and MPV/platelet count ratio have a prognostic significance in advanced NSCLC or not Methods:A total of 496 NSCLC patients at stage IIIB/IV and did not meet exclusion criteria were included in the study. The demographic fetaures (age, gender, smoking habit), clinical characteristics (performance status, weight loss, disease stage, first-line treatment regimen), laboratory tests (levels of hemoglobin, lactate dehydrogenase and calcium as well as MPV, MPV/platelet count ratio and counts of white blood cell, platelet), and histological features (histologic type, tumor grade) were recorded...
December 27, 2016: Clinical Respiratory Journal
keyword
keyword
41253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"